In summary, the combination regimen of toripalimab with chemotherapy for treatment-naïve patients with advanced NSCLC lacking EGFR/ALK driver mutations led to better OS compared to chemotherapy alone. Here, EGFR is linked to non-small cell lung carcinoma.